Akums Drugs and Pharmaceuticals Ltd (AKUMS) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Akums Drugs & Pharmaceuticals Ltd experienced flat revenue growth in FY25 due to significant price erosion in APIs and muted volumes, impacting the core CDMO business and delaying the turnaround of the API business.
- Despite headwinds, the company maintained margins and generated healthy cash flow.
- Q4 volumes grew by 9% year-on-year, while FY25 volumes grew by 1%, exceeding overall market volume growth.
- R&D spending increased by 16% to INR130 crores.
- The company launched 31 DCGI products and expanded capabilities in various drug delivery formats.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.